
-
Inventiva NasdaqGM:IVA Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France.
Location: 50 rue de Dijon, Daix, 21121, France | Website: https://www.inventivapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
381.8M
Cash
96.91M
Avg Qtr Burn
-21.48M
Short % of Float
0.73%
Insider Ownership
0.00%
Institutional Own.
5.09%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lanifibranor (Pan-PPAR) Details Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 Data readout | |
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes | Phase 2a Update | |
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma | Failed Discontinued | |
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder | Failed Discontinued |